$1.64
1.86% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US19188J3005
Symbol
COCP
Sector
Industry

Cocrystal Pharma Inc Stock price

$1.64
+0.08 4.79% 1M
-0.24 12.77% 6M
-0.38 18.81% YTD
-1.08 39.71% 1Y
-10.96 86.98% 5Y
-423.16 99.61% 10Y
+1.54 1,540.00% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
+0.03 1.86%
ISIN
US19188J3005
Symbol
COCP
Sector
Industry

Key metrics

Market capitalization $16.69m
Enterprise Value $9.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.28
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-16.06m
Free Cash Flow (TTM) Free Cash Flow $-14.81m
Cash position $6.92m
EPS (TTM) EPS $-1.56
P/E forward negative
Short interest 0.18%
Show more

Is Cocrystal Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Cocrystal Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cocrystal Pharma Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Cocrystal Pharma Inc:

Buy
100%

Financial data from Cocrystal Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.11 5.11
15% 15%
-
- Research and Development Expense 11 11
23% 23%
-
-16 -16
8% 8%
-
- Depreciation and Amortization 0.11 0.11
39% 39%
-
EBIT (Operating Income) EBIT -16 -16
9% 9%
-
Net Profit -16 -16
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cocrystal Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cocrystal Pharma Inc Stock News

Neutral
GlobeNewsWire
7 days ago
BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) being held August 4-7 in Kissimmee, Fla.
Neutral
GlobeNewsWire
14 days ago
CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company's virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the 2024 H5N1 avian influenza virus BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that a rece...
Neutral
GlobeNewsWire
15 days ago
BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will participate in a fireside chat during the Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference on Thursday, June 5, 2025 at 12:00 p.m.
More Cocrystal Pharma Inc News

Company Profile

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.

Head office United States
CEO Sam Lee
Employees 11
Founded 2008
Website www.cocrystalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today